Pill to treat COVID-19 cuts the risk of death by half, says Merck, which will seek its emergency authorization

Clinical trials show an experimental pill to treat COVID-19 cut the risk of death or hospitalizations by half. The companies who’ve developed the treatment - Merck and Ridgeback Biotherapeutics - say they’ll be seeking Emergency Use Authorization as soon as possible.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting